MEA Infectious Disease Diagnostics Market

MEA Infectious Disease Diagnostics Market Size (2023 to 2028)

The Middle East and Africa infectious disease diagnostics market is anticipated to grow at 9.42% CAGR from 2023 to 2028. The Middle East and Africa market is anticipated to grow to USD 2.54 billion by 2028 from USD 1.61 billion in 2023.

Factors such as increased awareness of early detection and prevention through specific diagnostic tests and high epidemiological burden of infectious diseases such as Ebola, Severe Acute Respiratory Syndrome (SARS), Zika, Middle East Respiratory Syndrome (MERS), Avian Flu, Chikungunya, Swine Flu are driving the infectious disease diagnostics market in the Middle East and African region. Moreover, increased awareness and acceptance of personalized medicines and funding for infectious disease diagnostic research further promote market growth.

In addition, the shift from centralized laboratories to decentralized point-of-care testing services benefits the user through the provision of real-time testing at the bedside. Rapid tests giving helpful information for diagnosis for initial treatment in a much shorter time, leading to its high adoption, are other factors propelling the MEA infectious disease diagnostics market. Furthermore, the increasing adoption of technologically advanced diagnostic equipment in healthcare organizations with reduced cost and faster test results, giving better patient outcomes, is also anticipated to augment the overall market growth in this region.

However, some countries' unfavorable reimbursement scenarios by healthcare insurance companies and the lack of high-complexity test centers in the African region for diagnosis of higher and dreadful pathogens hamper the growth of the infectious disease diagnostics market in the MEA region.

This research report on the MEA infectious disease diagnostics market has been segmented and sub-segmented into the following categories:

By Product: 

• Instruments
• Reagents
• Services
• Software

By Application: 

• Hepatitis C
• AIDS
• Tuberculosis

By Technology: 

• PCR
• INAAT
• DNA Sequencing
• Hybridization

By End User: 

• Hospital
• Laboratories

By Country:  

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Among all regions, the MEA region had a minor portion of the global market in 2022. However, the market is anticipated to grow at a moderate CAGR during the forecast period owing to the increasing population suffering from infectious diseases. As reported by WHO, 2,600 cases have been recorded since the first report of MERS-CoV in 2012, in addition to 935 associated deaths. The high burden of infectious diseases and added chronic diseases resulting from prolonged infectious diseases are expected to be a driving factor for the Middle East and African market, especially in Saudi Arabia. In addition, a large number of funds to perform R&D in the Middle Eastern region due to the acceptance of personalized medicine and better techniques to diagnose and monitor these diseases is anticipated to drive the regional market growth.

Most players of the key market players in Saudi Arabia focus on molecular diagnostics development to provide products such as kits and reagents, instruments, and software as a result of continued increase in health expenditure and increased awareness of early disease detection, resulting in regular health checks, strengthening of research-based diagnostic procedures and increase in the establishment of hospitals, clinical diagnostic laboratories for its applications in various disease indications, further enabling efficient treatment selection, diagnosis, treatment monitoring, and dose selection. Therefore, all the above factors are anticipated to drive the infectious disease diagnostics market in the Middle East and Africa.

KEY MARKET PLAYERS:

A few of the leading companies leading in the MEA Infectious Disease Diagnostics Market profiled in the report are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.